Published in J Virol on June 01, 1989
Functional roles for the TATA promoter and enhancers in basal and Tat-induced expression of the human immunodeficiency virus type 1 long terminal repeat. J Virol (1992) 2.93
In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor. J Virol (1993) 2.15
TAR independent activation of the human immunodeficiency virus in phorbol ester stimulated T lymphocytes. EMBO J (1990) 2.00
Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production. J Virol (1994) 1.98
Molecular pathways in virus-induced cytokine production. Microbiol Mol Biol Rev (2001) 1.97
Linker-scanning mutational analysis of the transcriptional activity of the human immunodeficiency virus type 1 long terminal repeat. J Virol (1991) 1.84
RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type 1 replication. J Virol (2002) 1.80
Upstream U3 sequences in simian immunodeficiency virus are selectively deleted in vivo in the absence of an intact nef gene. J Virol (1994) 1.77
RNA motif discovery by SHAPE and mutational profiling (SHAPE-MaP). Nat Methods (2014) 1.72
Human chromosome 12 is required for optimal interactions between Tat and TAR of human immunodeficiency virus type 1 in rodent cells. J Virol (1992) 1.69
Efficient trans-activation by the HIV-2 Tat protein requires a duplicated TAR RNA structure. Nucleic Acids Res (1990) 1.67
Different members of the Sp1 multigene family exert opposite transcriptional regulation of the long terminal repeat of HIV-1. Nucleic Acids Res (1994) 1.65
A discrete cis element in the human immunodeficiency virus long terminal repeat mediates synergistic trans activation by cytomegalovirus immediate-early proteins. J Virol (1991) 1.62
Modulation of Sp1 phosphorylation by human immunodeficiency virus type 1 Tat. J Virol (1998) 1.53
Variable role of the long terminal repeat Sp1-binding sites in human immunodeficiency virus replication in T lymphocytes. J Virol (1991) 1.45
Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol (2010) 1.40
Naturally occurring genotypes of the human immunodeficiency virus type 1 long terminal repeat display a wide range of basal and Tat-induced transcriptional activities. J Virol (1994) 1.40
Efficient transcription and replication of simian immunodeficiency virus in the absence of NF-kappaB and Sp1 binding elements. J Virol (1996) 1.39
Replication of type 1 human immunodeficiency viruses containing linker substitution mutations in the -201 to -130 region of the long terminal repeat. J Virol (1993) 1.37
Synergistic activation of a human promoter in vivo by transcription factor Sp1. Mol Cell Biol (1991) 1.34
Differential growth kinetics are exhibited by human immunodeficiency virus type 1 TAR mutants. J Virol (1994) 1.27
COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells. Nucleic Acids Res (2005) 1.26
Synergistic activation of the human immunodeficiency virus type 1 promoter by the viral Tat protein and cellular transcription factor Sp1. J Virol (1992) 1.25
Identification of a transactivating function mapping to the putative immediate-early locus of human herpesvirus 6. J Virol (1991) 1.24
Lineage-specific and ubiquitous biological roles of the mammalian transcription factor LSF. Gene (2004) 1.21
The cellular factor TRP-185 regulates RNA polymerase II binding to HIV-1 TAR RNA. EMBO J (1995) 1.20
Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage. Retrovirology (2009) 1.17
Role of flanking E box motifs in human immunodeficiency virus type 1 TATA element function. J Virol (1994) 1.17
cis-acting sequences located downstream of the human immunodeficiency virus type 1 promoter affect its chromatin structure and transcriptional activity. Mol Cell Biol (1996) 1.14
Sp1 transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat. J Virol (1995) 1.11
Human T cell transcription factor GATA-3 stimulates HIV-1 expression. Nucleic Acids Res (1993) 1.10
Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms. J Virol (1993) 1.10
Multiple transcriptional regulatory domains in the human immunodeficiency virus type 1 long terminal repeat are involved in basal and E1A/E1B-induced promoter activity. J Virol (1989) 1.07
Induction of AIDS by simian immunodeficiency virus lacking NF-kappaB and SP1 binding elements. J Virol (1997) 1.07
Increased spacing between Sp1 and TATAA renders human immunodeficiency virus type 1 replication defective: implication for Tat function. J Virol (1993) 1.06
The tumor suppressor protein p53 strongly alters human immunodeficiency virus type 1 replication. J Virol (1994) 1.06
The ZiN/POZ domain of ZF5 is required for both transcriptional activation and repression. Nucleic Acids Res (1997) 1.04
The NF-kappa B and Sp1 motifs of the human immunodeficiency virus type 1 long terminal repeat function as novel thyroid hormone response elements. Mol Cell Biol (1993) 1.04
O-linked N-acetylglucosaminylation of Sp1 inhibits the human immunodeficiency virus type 1 promoter. J Virol (2009) 1.03
Analysis of proteins binding to the proximal promoter region of the human cytomegalovirus IE-1/2 enhancer/promoter reveals both consensus and aberrant recognition sequences for transcription factors Sp1 and CREB. Nucleic Acids Res (1992) 1.02
NF-kappa B homodimer binding within the HIV-1 initiator region and interactions with TFII-I. Proc Natl Acad Sci U S A (1996) 1.00
Genotypic and phenotypic characterization of long terminal repeat sequences from long-term survivors of human immunodeficiency virus type 1 infection. J Virol (1997) 0.99
Identification of a replication-competent pathogenic human immunodeficiency virus type 1 with a duplication in the TCF-1alpha region but lacking NF-kappaB binding sites. J Virol (1997) 0.97
Sequences just upstream of the simian immunodeficiency virus core enhancer allow efficient replication in the absence of NF-kappaB and Sp1 binding elements. J Virol (1998) 0.97
Promoter scanning for transcription inhibition with DNA-binding polyamides. Mol Cell Biol (2002) 0.96
Human immunodeficiency virus type 1 infection of the brain. Clin Microbiol Rev (1993) 0.94
Functional interactions between C/EBP, Sp1, and COUP-TF regulate human immunodeficiency virus type 1 gene transcription in human brain cells. J Virol (2000) 0.92
Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT. J Virol (1998) 0.91
The HIV-1 Tat protein has a versatile role in activating viral transcription. J Virol (2011) 0.91
A novel HIV-1-encoded microRNA enhances its viral replication by targeting the TATA box region. Retrovirology (2014) 0.89
T helper cell activation and human retroviral pathogenesis. Microbiol Rev (1996) 0.88
Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription. Antimicrob Agents Chemother (2004) 0.87
HMGA1 directly interacts with TAR to modulate basal and Tat-dependent HIV transcription. RNA Biol (2013) 0.86
Genetic selection for context-dependent stochastic phenotypes: Sp1 and TATA mutations increase phenotypic noise in HIV-1 gene expression. PLoS Comput Biol (2013) 0.86
CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies. Mol Psychiatry (2015) 0.85
The CD8 antiviral factor (CAF) can suppress HIV-1 transcription from the long terminal repeat (LTR) promoter in the absence of elements upstream of the CATATAA box. Virol J (2014) 0.82
Activation of a heterologous promoter by human immunodeficiency virus type 1 Tat requires Sp1 and is distinct from the mode of activation by acidic transcriptional activators. J Virol (1993) 0.81
Mutations generated in human immunodeficiency virus type 1 long terminal repeat during vertical transmission correlate with viral gene expression. Virology (2008) 0.80
The Role of RNA Polymerase II Elongation Control in HIV-1 Gene Expression, Replication, and Latency. Genet Res Int (2011) 0.80
In vivo transcriptional regulation of the human immunodeficiency virus in the central nervous system in transgenic mice. J Virol (1996) 0.79
The activation region of the Tat protein of human immunodeficiency virus type-1 functions in yeast. Nucleic Acids Res (1994) 0.79
The variances of Sp1 and NF-κB elements correlate with the greater capacity of Chinese HIV-1 B'-LTR for driving gene expression. Sci Rep (2016) 0.76
HIV‑1 downregulates the expression and phosphorylation of receptor tyrosine kinase by targeting the NF‑κB pathway. Mol Med Rep (2016) 0.75
Opinion: Inhibition of Blood-Brain Barrier Repair as a Mechanism in HIV-1 Disease. Front Neurosci (2017) 0.75
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res (1983) 124.30
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol (1982) 116.75
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61
Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science (1984) 32.33
DNAse footprinting: a simple method for the detection of protein-DNA binding specificity. Nucleic Acids Res (1978) 30.43
An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature (1987) 19.23
The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. Cell (1983) 15.09
Affinity purification of sequence-specific DNA binding proteins. Proc Natl Acad Sci U S A (1986) 14.92
Interaction of a gene-specific transcription factor with the adenovirus major late promoter upstream of the TATA box region. Cell (1985) 13.36
Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science (1985) 12.75
HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA. Cell (1986) 12.74
Purification and biochemical characterization of the promoter-specific transcription factor, Sp1. Science (1986) 12.58
Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell (1987) 12.30
The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell (1985) 11.28
Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein. Cell (1987) 11.15
Two distinct transcription factors bind to the HSV thymidine kinase promoter in vitro. Cell (1985) 11.03
The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell (1986) 10.76
A second post-transcriptional trans-activator gene required for HTLV-III replication. Nature (1986) 10.76
Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell (1986) 10.71
Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III. Science (1985) 10.36
Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature (1988) 10.15
Isolation of transcription factors that discriminate between different promoters recognized by RNA polymerase II. Cell (1983) 8.85
The trans-activator gene of HTLV-III is essential for virus replication. Nature (1986) 8.65
Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1. Science (1986) 8.01
The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell (1988) 7.76
Positive and negative regulation of transcription in vitro: enhancer-binding protein AP-2 is inhibited by SV40 T antigen. Cell (1987) 7.51
HIV-1 tat trans-activation requires the loop sequence within tar. Nature (1988) 6.87
Multiple specific contacts between a mammalian transcription factor and its cognate promoters. Nature (1985) 6.77
Activation of transcription by two factors that bind promoter and enhancer sequences of the human metallothionein gene and SV40. Nature (1987) 6.76
Elevated levels of mRNA can account for the trans-activation of human immunodeficiency virus. Proc Natl Acad Sci U S A (1986) 6.57
Post-transcriptional regulation accounts for the trans-activation of the human T-lymphotropic virus type III. Nature (1986) 5.24
Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I. Science (1987) 5.22
Expression and characterization of the trans-activator of HTLV-III/LAV virus. Science (1986) 5.15
Bidirectional SV40 transcription mediated by tandem Sp1 binding interactions. Science (1985) 5.00
Nef protein of HIV-1 is a transcriptional repressor of HIV-1 LTR. Science (1988) 5.00
Trans-activation of human immunodeficiency virus gene expression is mediated by nuclear events. Proc Natl Acad Sci U S A (1987) 4.91
Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc Natl Acad Sci U S A (1986) 4.89
Identification and purification of a human immunoglobulin-enhancer-binding protein (NF-kappa B) that activates transcription from a human immunodeficiency virus type 1 promoter in vitro. Proc Natl Acad Sci U S A (1988) 4.33
Transcription factor ATF interacts with the TATA factor to facilitate establishment of a preinitiation complex. Cell (1988) 4.15
Interactions of cellular proteins involved in the transcriptional regulation of the human immunodeficiency virus. EMBO J (1987) 4.14
A discrete element 3' of human immunodeficiency virus 1 (HIV-1) and HIV-2 mRNA initiation sites mediates transcriptional activation by an HIV trans activator. Mol Cell Biol (1988) 3.74
Mutational analysis of the trans-activation-responsive region of the human immunodeficiency virus type I long terminal repeat. J Virol (1988) 3.69
Structural arrangements of transcription control domains within the 5'-untranslated leader regions of the HIV-1 and HIV-2 promoters. Genes Dev (1988) 3.51
Human immunodeficiency virus long terminal repeat responds to T-cell activation signals. Proc Natl Acad Sci U S A (1987) 3.47
Purification of the human immunodeficiency virus type 1 enhancer and TAR binding proteins EBP-1 and UBP-1. EMBO J (1988) 2.74
Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat. EMBO J (1988) 2.57
Phorbol ester enhances human immunodeficiency virus-promoted gene expression and acts on a repeated 10-base-pair functional enhancer element. Mol Cell Biol (1987) 2.42
Transcriptional but not translational regulation of HIV-1 by the tat gene product. Nature (1988) 2.15
Demonstration of virus-specific transcriptional activator(s) in cells infected with HTLV-III by an in vitro cell-free system. Cell (1986) 2.13
In vitro activation of the HIV-1 enhancer in extracts from cells treated with a phorbol ester tumor promoter. EMBO J (1987) 2.09
Alterations in binding characteristics of the human immunodeficiency virus enhancer factor. J Virol (1988) 1.88
miR-21-mediated tumor growth. Oncogene (2006) 9.90
WHO antenatal care randomised trial for the evaluation of a new model of routine antenatal care. Lancet (2001) 6.86
Making sense of randomization; responses of parents of critically ill babies to random allocation of treatment in a clinical trial. Soc Sci Med (1997) 6.73
Recruitment to randomised trials: strategies for trial enrollment and participation study. The STEPS study. Health Technol Assess (2007) 6.55
Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol (1995) 5.18
Interleukin-2 therapy in patients with HIV infection. N Engl J Med (2009) 4.38
Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. EMBO J (1989) 4.24
Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res (1997) 4.22
Interactions of cellular proteins involved in the transcriptional regulation of the human immunodeficiency virus. EMBO J (1987) 4.14
West Berkshire perineal management trial. Br Med J (Clin Res Ed) (1984) 3.85
Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells. J Exp Med (1997) 3.74
Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA (1999) 3.69
Reactions of participants to the results of a randomised controlled trial: exploratory study. BMJ (1998) 2.83
The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population. Br J Cancer (2005) 2.66
Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat. EMBO J (1988) 2.57
The American Stop Smoking Intervention Study. Conceptual framework and evaluation design. Eval Rev (1999) 2.57
Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A (2000) 2.54
Indian Agarwal megalencephalic leukodystrophy with cysts is caused by a common MLC1 mutation. Neurology (2004) 2.48
Zelen randomization: attitudes of parents participating in a neonatal clinical trial. Control Clin Trials (1999) 2.37
Epidemiological and transmissibility analysis of influenza A(H1N1)v in a southern hemisphere setting: Peru. Euro Surveill (2009) 2.35
tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185. Genes Dev (1991) 2.34
Rebound bilirubin levels in infants receiving phototherapy. J Pediatr (1998) 2.19
Novel, ligation-dependent PCR assay for detection of hepatitis C in serum. J Clin Microbiol (1996) 2.19
Specific binding of a HeLa cell nuclear protein to RNA sequences in the human immunodeficiency virus transactivating region. Proc Natl Acad Sci U S A (1989) 2.17
Variables that affect assays for plasma cytokines and soluble activation markers. Clin Diagn Lab Immunol (1999) 2.15
Patients with chronic obstructive pulmonary disease are at increased risk of death associated with urban particle air pollution: a case-crossover analysis. Am J Epidemiol (2000) 2.15
High-intensity focused ultrasound for the treatment of liver tumours. Ultrasonics (2004) 2.14
Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine (1995) 2.06
TAR independent activation of the human immunodeficiency virus in phorbol ester stimulated T lymphocytes. EMBO J (1990) 2.00
A randomised controlled trial of care of the perineum during second stage of normal labour. Br J Obstet Gynaecol (1998) 1.96
Alterations in binding characteristics of the human immunodeficiency virus enhancer factor. J Virol (1988) 1.88
The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg (1998) 1.83
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy (1999) 1.83
KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia (2009) 1.80
CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant V alpha 24 J alpha Q T cell receptor alpha chains. J Exp Med (1998) 1.80
Labour and birth in water in England and Wales. BMJ (1995) 1.79
Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol (2007) 1.78
Vi serology in detection of chronic Salmonella typhi carriers in an endemic area. Lancet (1983) 1.78
Ultrasound screening in pregnancy: a systematic review of the clinical effectiveness, cost-effectiveness and women's views. Health Technol Assess (2000) 1.74
Young people and healthy eating: a systematic review of research on barriers and facilitators. Health Educ Res (2005) 1.70
Effect of chronic salt loading on adenosine metabolism and receptor expression in renal cortex and medulla in rats. Hypertension (1999) 1.64
Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl (2002) 1.63
A discrete cis element in the human immunodeficiency virus long terminal repeat mediates synergistic trans activation by cytomegalovirus immediate-early proteins. J Virol (1991) 1.62
Negative regulation of lncRNA GAS5 by miR-21. Cell Death Differ (2013) 1.60
Trial experience and problems of parental recollection of consent. BMJ (2001) 1.60
Elevated circulating endothelial microparticles and brachial-ankle pulse wave velocity in well-controlled hypertensive patients. J Hum Hypertens (2008) 1.57
A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci U S A (1990) 1.55
trans-activation of viral enhancers including long terminal repeat of the human immunodeficiency virus by the hepatitis B virus X protein. Virology (1989) 1.55
Limited sequence heterogeneity among biologically distinct human immunodeficiency virus type 1 isolates from individuals involved in a clustered infectious outbreak. Proc Natl Acad Sci U S A (1990) 1.54
Employment in pregnancy: prevalence, maternal characteristics, perinatal outcome. Lancet (1984) 1.54
Perinatal pathology in the context of a clinical trial: attitudes of bereaved parents. Arch Dis Child Fetal Neonatal Ed (2004) 1.54
Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients. J Immunol (1988) 1.54
Stimulation of NFkappa B activity by multiple signaling pathways requires PAK1. J Biol Chem (2000) 1.49
Pregnant women at work. Lancet (1983) 1.48
The oculocardiac reflex in cataract surgery in the elderly. Br J Ophthalmol (1997) 1.47
CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology (2000) 1.46
Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species. J Biol Chem (2000) 1.45
Allergy to penicillin with good tolerance to other penicillins; study of the incidence in subjects allergic to beta-lactams. Clin Exp Allergy (1990) 1.45
Interaction between protein kinase C delta and the c-Abl tyrosine kinase in the cellular response to oxidative stress. J Biol Chem (2000) 1.43
Upstream regulatory regions required to stabilize binding to the TATA sequence in an adenovirus early promoter. Nucleic Acids Res (1987) 1.43
A solution to diffraction biases in sonoelasticity: the acoustic impulse technique. J Acoust Soc Am (1999) 1.43
A comparative analysis of conservative versus surgical treatment of Morton's neuroma. J Am Podiatr Med Assoc (1989) 1.42
Selective immediate allergic response to penicillin V. Allergy (1996) 1.41
Breast feeding policies in practice--'no wonder they get confused'. Midwifery (1989) 1.41
Changes in reticulocyte fractions during peripheral stem cell harvesting: role in monitoring stem cell collection. Bone Marrow Transplant (1996) 1.41
Attention-deficit hyperactivity disorder and juvenile mania: an overlooked comorbidity? J Am Acad Child Adolesc Psychiatry (1996) 1.41
Praseodymium hydroxide and oxide nanorods and Au/Pr6O11 nanorod catalysts for CO oxidation. J Phys Chem B (2006) 1.40
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol (2007) 1.39
Chronic intrahepatic cholestasis and Sicca syndrome of sarcoidosis. J Hepatol (1993) 1.39
Cardiac power index: staging heart failure for mechanical circulatory support. Perfusion (2012) 1.39
Perinatal pathology in the context of a clinical trial: attitudes of neonatologists and pathologists. Arch Dis Child Fetal Neonatal Ed (2004) 1.39
Flavor-illness aversions: potentiation of odor by taste in rats. Behav Neural Biol (1979) 1.37
Characterization and chromosomal mapping of the gene encoding the cellular DNA binding protein HTLF. Genomics (1992) 1.36
Perinatal pathology in the context of a clinical trial: a review of the literature. Arch Dis Child Fetal Neonatal Ed (2004) 1.31
Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene (2009) 1.31
The human T-cell leukemia virus type 1 transactivator protein Tax colocalizes in unique nuclear structures with NF-kappaB proteins. J Virol (1997) 1.28
S100 protein: a marker for human malignant melanomas? Lancet (1981) 1.27
Thrombotic risk factors in Chinese Budd-Chiari syndrome patients. An observational study with a systematic review of the literature. Thromb Haemost (2013) 1.25
Limited human-to-human transmission of avian influenza A(H7N9) virus, Shanghai, China, March to April 2013. Euro Surveill (2014) 1.25
Limited sequence variation in human T-lymphotropic virus type 1 isolates from North American and African patients. Virology (1991) 1.24
Long-lived ultrafast spin precession in manganese alloys films with a large perpendicular magnetic anisotropy. Phys Rev Lett (2011) 1.23
Randomized study of algorithms for discontinuing tube thoracostomy drainage. J Am Coll Surg (1994) 1.23
Thiosulfate reduction, an important physiological feature shared by members of the order thermotogales. Appl Environ Microbiol (1995) 1.22
A general theory of aversion learning. Ann N Y Acad Sci (1985) 1.21
Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile. Epidemiol Infect (1990) 1.21
Training programs for healthcare professionals in domestic violence. J Womens Health Gend Based Med (2001) 1.21
The program for in vitro fertilization at Norfolk. Fertil Steril (1982) 1.21
T, B and K cells in autoimmune thyroid disease. Clin Exp Immunol (1976) 1.20
Prevention of nosocomial lung infection in ventilated patients: use of an antimicrobial pharyngeal nonabsorbable paste. Crit Care Med (1990) 1.19
Appendicitis as a complication of colonoscopy. Gastrointest Endosc (1995) 1.19